Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer's disease
- PMID:14675732
- DOI: 10.1016/s0197-4580(03)00117-9
Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer's disease
Abstract
Converging evidence supports the role of oxidative stress in the pathology of Alzheimer's disease (AD). This notion is further supported by recent findings of increased NAD(P)H:quinone oxidodreductase (NQO1) activity, a potent antioxidant system, in association with hippocampal AD pathology. If increased NQO1 activity is truly related to the AD process, however, we would expect to see regional co-localization of NQO1 activity with AD pathology throughout affected brain regions and the absence of NQO1 activity in regions unaffected by AD. We examined this hypothesis by measuring NQO1 enzymatic activity and NQO1 immunohistochemical staining in regions commonly affected by the AD process such as frontal cortex and compared this to regions generally unaffected by the AD process such as occipital cortex, cerebellum, and substantia nigra for a group of AD patients and controls. The ratio of frontal to cerebellar NQO1 enzymatic activity was significantly increased in patients with AD (2.07 +/- 1.90) versus controls (0.60 +/- 0.31; P < 0.03). Moreover, regional immunohistochemical staining revealed specific localization of NQO1 staining to astrocytes and neurites surrounding senile plaques. The extent of immunohistochemical staining also closely correlated with the extent of local AD pathology across the various brain regions examined. Neuronal NQO1 staining seen in frontal cortex of AD patients was absent in frontal cortex of controls, but was found to the same extent in neurons of the substantia nigra of both AD patients and controls. We conclude that NQO1 activity co-localizes closely with AD pathology supporting a presumed role as an antioxidant system upregulated in response to the oxidative stress of the AD process. The antioxidant role for NQO1 is further supported by finding increased neuronal NQO1 activity in substantia nigra neurons of both AD patients and controls as this neuronal population is known to be under constant oxidative stress. While requiring further study, these findings, in conjunction with previous work, suggest that increased NQO1 activity may be neuroprotective, may offer novel insights into the pathophysiology of AD and may also provide possible avenues for future treatment.
Similar articles
- Alzheimer's Disease and NQO1: Is there a Link?Chhetri J, King AE, Gueven N.Chhetri J, et al.Curr Alzheimer Res. 2018;15(1):56-66. doi: 10.2174/1567205014666170203095802.Curr Alzheimer Res. 2018.PMID:28164770Review.
- NAD(P)H:quinone oxidoreductase activity is increased in hippocampal pyramidal neurons of patients with Aalzheimer's disease.Wang Y, Santa-Cruz K, DeCarli C, Johnson JA.Wang Y, et al.Neurobiol Aging. 2000 Jul-Aug;21(4):525-31. doi: 10.1016/s0197-4580(00)00114-7.Neurobiol Aging. 2000.PMID:10924765
- Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra.van Muiswinkel FL, de Vos RA, Bol JG, Andringa G, Jansen Steur EN, Ross D, Siegel D, Drukarch B.van Muiswinkel FL, et al.Neurobiol Aging. 2004 Oct;25(9):1253-62. doi: 10.1016/j.neurobiolaging.2003.12.010.Neurobiol Aging. 2004.PMID:15312971
- Association analysis of NAD(P)H:quinone oxidoreductase gene 609 C/T polymorphism with Alzheimer's disease.Wang B, Jin F, Xie Y, Tang Y, Kan R, Zheng C, Yang Z, Wang L.Wang B, et al.Neurosci Lett. 2006 Dec 6;409(3):179-81. doi: 10.1016/j.neulet.2006.09.042. Epub 2006 Oct 5.Neurosci Lett. 2006.PMID:17027152
- NQO1: A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms.Beaver SK, Mesa-Torres N, Pey AL, Timson DJ.Beaver SK, et al.Biochim Biophys Acta Proteins Proteom. 2019 Jul-Aug;1867(7-8):663-676. doi: 10.1016/j.bbapap.2019.05.002. Epub 2019 May 12.Biochim Biophys Acta Proteins Proteom. 2019.PMID:31091472Review.
Cited by
- The Emerging Roles of Antioxidant Enzymes by Dietary Phytochemicals in Vascular Diseases.Lee SE, Park YS.Lee SE, et al.Life (Basel). 2021 Mar 4;11(3):199. doi: 10.3390/life11030199.Life (Basel). 2021.PMID:33806594Free PMC article.Review.
- Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology.Jiwaji Z, Tiwari SS, Avilés-Reyes RX, Hooley M, Hampton D, Torvell M, Johnson DA, McQueen J, Baxter P, Sabari-Sankar K, Qiu J, He X, Fowler J, Febery J, Gregory J, Rose J, Tulloch J, Loan J, Story D, McDade K, Smith AM, Greer P, Ball M, Kind PC, Matthews PM, Smith C, Dando O, Spires-Jones TL, Johnson JA, Chandran S, Hardingham GE.Jiwaji Z, et al.Nat Commun. 2022 Jan 10;13(1):135. doi: 10.1038/s41467-021-27702-w.Nat Commun. 2022.PMID:35013236Free PMC article.
- NQO1 regulates expression and alternative splicing of apoptotic genes associated with Alzheimer's disease in PC12 cells.Du Y, Liu G, Chen D, Yang J, Wang J, Sun Y, Zhang Q, Liu Y.Du Y, et al.Brain Behav. 2023 May;13(5):e2917. doi: 10.1002/brb3.2917. Epub 2023 Mar 31.Brain Behav. 2023.PMID:37002649Free PMC article.
- Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders.Brandebura AN, Paumier A, Onur TS, Allen NJ.Brandebura AN, et al.Nat Rev Neurosci. 2023 Jan;24(1):23-39. doi: 10.1038/s41583-022-00641-1. Epub 2022 Oct 31.Nat Rev Neurosci. 2023.PMID:36316501Free PMC article.Review.
- Network pharmacology identify intersection genes of quercetin and Alzheimer's disease as potential therapeutic targets.Wei C, Li S, Zhu Y, Chen W, Li C, Xu R.Wei C, et al.Front Aging Neurosci. 2022 Aug 23;14:902092. doi: 10.3389/fnagi.2022.902092. eCollection 2022.Front Aging Neurosci. 2022.PMID:36081896Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous